SynthesisHaemophilia : the official journal of the World Federation of Hemophilia2025
Determining the Impact of Combination Oral Contraceptives on Von Willebrand Factor and Factor VIII in Healthy Patients and Patients With Von Willebrand Disease: A Scoping Review and Meta-Analysis.
Synthesis in Haemophilia : the official journal of the World Federation of Hemophilia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Determining the Impact of Combination Oral Contraceptives on Von Willebrand Factor and Factor VIII in Healthy Patients and Patients With Von Willebrand Disease: A Scoping Review and Meta-Analysis.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Pooled it
- Call to action: identifying an underlying bleeding disorder in adolescents with heavy menstrual bleeding.Research and practice in thrombosis and haemostasis · 2026Review
- Assessing the Impact of the 2021 VWD Guidelines on the Diagnosis/Management of Low VWF Patients.Haemophilia : the official journal of the World Federation of HemophiliaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVon Willebrand disease (VWD) is a bleeding disorder characterized by a deficiency or dysfunction of Von Willebrand factor (VWF) and/or Factor VIII (FVIII), critical coagulation proteins. Individuals with VWD often use combination oral contraceptives (COCs) to manage heavy menstrual bleeding. However, the impact of COCs on VWF and FVIII levels and whether COC use affects VWD diagnosis is unclear.
aimTo review the literature and assess the impact of COCs on FVIII and VWF.
methodsThis scoping review used the OVID platform in the MEDLINE, EMBASE and Cochrane databases. Keywords "combination oral contraceptives," "von Willebrand Factor," "Factor VIII" and "von Willebrand Disease" were searched. Primary studies exploring the impact of COCs on VWF and/or FVIII in patients of reproductive age were included. Article titles and abstracts were screened, followed by full-text reviews, data extraction and a meta-analysis.
resultsTwenty-seven studies were included. In healthy patients, 11 studies reported no change in VWF levels, while three found changes in VWF levels. Nine studies reported no change in FVIII levels, while 10 studies observed an increase. In patients with VWD, two studies found no significant change in VWF or FVIII levels. Meta-analysis revealed there was no significant difference in VWF% (Estimate: 2.62 (95%CI -0.5905, 5.831); p value: 0.4033) or FVIII% (Estimate: 2.99 (95%CI -4.85, 10.82); p value: 0.4552) with COC use.
conclusionThe meta-analysis revealed no difference in VWD or FVIII levels between participants with and without COCs. The lack of observed differences suggests that COCs do not interfere with accurate VWD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.